engleski

Effects of glucagon-like peptide-1 receptor agonist liraglutide on blood pressure and heart rate in overweight type 2 diabetic patients

Glucagon-lik epeptide-1 (GLP-1) agonists are increasingly used in the management of type 2 diabetes mellitus(T2DM), but their long-term cardiovascular safety is not yet confirmed. In the present study, we assessed effects of liraglutide on systolic blood pressure(SBP), diastolic blood pressure(DBP)and HR in overweight T2DM. The results of our study suggest that therapy with GLP-1 receptor agonist liraglutide may significantly reduce SBP and DBP by 6 to 10 mmHg and may offer an alternative therapy for hypertension in overweight T2DM. In addition, in our study therapy with liraglutide was associated with a small decrease in HR.

glucagon-like peptide-1; blood pressure; heart rate

nije evidentirano